What is taking so long for AF and others to comments good or bad ?
Clearly, ThermoDox does not work with entire group under phase 3 study.
But maybe different with subgroup under very specific conditions. Now we know that Celsion should have been more selective with its study group, it was much too broad.
If any meanfull percent in any subgroup shows both PFS and OS... Phase 3 will be deemed successfull, for this subgroup.
Celsion pps will raise for sure and how much depends only of the size of this subgroup.
Looking for $ 2-3 pps with strong data and forthcoming peer support. Company has plenty of money to carry process to success with this subgroup only.
Sentiment: Strong Buy
KERX was set to release data late November, because of Sandy and Year End Holidays, there was substantial delays which gave blogges and shorts room to scare many.
At the end, top line data were better than great and pps doubled and even almost trippled.
Lewis said this week but specific day makes no difference to most, except day traders and people on margin.
Co has 24 hrs to release data when received,
KERX had more than 2 months delay and it made its shareholders very wealthy. Almost triple to the top before giving back some.
Phase 2 clearly indicated substantial percent increase in sudy group but there were wiggle room because of small number of patients and was not blinded study. Normal stuff and therefore blinded type phase 3 before NDA filling etc...
Lewis and crew have been closely following patients in ph 3 study group and as a group, they have to be noticing same nicely increased survival percent.
Yes, anecdotal results that should be put to rest for good this week with real top line data
We can easily believe that Lewis would not have started new studies and would have had secondairy funds raising before results, if there was no specific anecdotal indication that drug works.
Now, you have to decide how important "anecdotal indication" are in this situation
It would seem that Zerenex potential too big for small biotech Co.
Something is missing. Large Pharma Cos should be more interested, especially for Europe as partner is absolutely necessary.
You are right, Bentsur clearly indicated that there is no doubt anymore. Patents are secure, but.. These patenst, when will they be granted for good ?
Bad news are announced Friday late afternoon, not Tuesday morning at 8.30 AM after having issued statement for it just less than 24 hours before.
Especially with... What earnings ? just few millions from Japan and how long would it take to calculate.
Tomorrow is all about "business outlook for 2013"...
What better time than earnings and official CC to bring some real news ?
Should not be too surprising to hear something pleasant/good/great/ maybe even fantastic.
24 hrs notice is really short notice just for normal day to day 4th qtr call
So, you have followed a guy on TV and invested in biotech based on a guy that has opinions on all compagnies on every US stock exchanges.
Small biotech are much much more complicated than that.
Not really. He is right. And if he own KERX or not .. who cares !!!
Just saying KERX is complicated situation and not for all to invest in.
Anything different from all other small drug developping biotechs ?
Already double my investment and looking for another double from here, but am aware that risks are huge, just like my profit are and will be again.
Once again, do your own DD and hope for the best.
Just remenber that no pps increase when no risks and all news baked in
here at least, pps will jump forward nicely with good data , petents granted and FDA approval.
Nothing baked in yet and failure possible.
pps has increased minimum 30%, and for some double, since buying was done because of Perifo.
Shareholders just needed to hold another 10 months to make real money.
Those lawsuits should be difficult to justify it would seem.
In addition, don't biotech companies have insurance against this type of lawsuits ?
Cubist purchased Adolor under such agreement even before phase 3 program FDA established and NDA date scheduled. Win win for both companies, management and shareholders as well.
CPR agreement is ideal for biotech with just 1 drug in their pipeline like KERX.
Zerenex works and few deep pockets that paid $ 8.49 at last month secondairy know it.
And 4-5 weeks later, pps is low $ 7 ish.
Hummmm, should not stay like that past earnings and next PR/CC.
Maybe not buyout but partnership for sure.